论文部分内容阅读
Objective: To examine the prevalence of headache and migraine among women using oral contraceptives (OCs) in a large, cross- sectional population- based study. Methods: In the Nord- Tr ndelag Health Study in Norway 1995- 1997 (HUNT 2), 27,700 (60% ) out of 46,506 invited women responded to headache questions (Head- HUNT). Among 14,353 premenopausal women, 13,944 (97% ) responded to questions regarding use of contraceptives. Results: There was a significant association between headache and reported use of estrogen- containing OCs in premenopausal women, both for migraine (OR = 1.4, 95% CI = 1.2 to 1.7) and for non- migrainous headache (OR = 1.2, 95% CI = 1.0 to 1.4). A significant dose relationship between headache and the amount of estrogen in the OCs could not be demonstrated. No significant association between headache and OCs containing only gestagen was found. Conclusion: Headache, especially migraine, was more likely among premenopausal women using oral contraceptives containing estrogen.
Methods: In the Nord-Tröndelag Health Study in Norway 1995-1997 (HUNT 2) Methods: In the Nord-Tröndelag Health Study in Norway 1995-1997 (HUNT 2) , 27,700 (60%) out of 46,506 invited women responded to headache questions (Head- HUNT). Among 14,353 premenopausal women, 13,944 (97%) responded to questions regarding use of contraceptives. Results: There was a significant association between headache and reported use of estrogen-containing OCs in premenopausal women, both for migraine (OR = 1.4, 95% CI = 1.2 to 1.7) and for non- migrainous headache (OR = 1.2, 95% CI = 1.0 to 1.4) between headache and the amount of estrogen in the OCs could not be demonstrated. No significant association between headache and OCs containing only gestagen was found. Conclusion: Headache, especially migraine, was more likely among premenopausal women using oral contraceptives containin g estrogen.